Treats itching of the eye associated with allergic conjunctivitis. ANDA 78621, held by Apotex. Azelastine Hydrochloride.
As of Nov 16, 2026, ANDA 78621 (Azelastine Hydrochloride), held by Apotex, was first approved by FDA on Aug 3, 2009, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Azelastine hydrochloride ophthalmic solution is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azelastine Hydrochloride0.05% · solution/drops;ophthalmic | Azelastine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters